Cancer is the second cause of death worldwide, surpassed only by cardiovascular diseases,
due to the lack of early diagnosis, and high relapse rate after conventional therapies …

As adeno-associated virus (AAV)-based gene therapies are being increasingly approved for
use in humans, it is important that we understand vector–host interactions in detail. With the …

The global burden of hepatocellular carcinoma (HCC), one of the frequent causes of cancer-
related deaths worldwide, is rapidly increasing partly due to the limited treatment options …

Hepatocellular carcinoma (HCC) is a devastating disease worldwide. Though many efforts
have been made to elucidate the process of HCC, its molecular mechanisms of …

Adeno-associated virus (AAV) vectors have gained tremendous attention as in vivo delivery
systems in gene therapy for inherited monogenetic diseases. First market approvals …

Stem cell therapy holds immense potential as a viable treatment for a widespread range of
intractable disorders. As the safety of stem cell transplantation having been demonstrated in …

Understanding the molecular basis of disease and the design of rationally designed
molecular therapies has been the holy grail in the management of human cancers. Gene …

Primary liver cancer, which is scientifically referred to as hepatocellular carcinoma (HCC), is
a significant concern in the field of global health. It has been demonstrated that conventional …

Targeted gene delivery relies on the ability to limit the expression of a transgene within a
defined cell/tissue population. MicroRNAs represent a class of highly powerful and effective …

Introduction: This study reviews the evidence for the use of Bortezomib (BZB), a first-in-class
proteasome inhibitor in advanced Hepatocellular carcinoma (HCC). This review aims to …